Coronavirus (COVID-19) Collection
Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis
The COVID-19 pandemic continues to spread worldwide and to be one of the main problems affecting public health around the world. In Spain, according to data published by the Ministry of Health on April 13, 2022, 92.5% of the population aged over 12 years residing in Spain has received a complete vaccination pattern, with 92.9% having received at least one dose, achieving a protective effect against transmission of the virus (Ministerio de Sanidad. Gobierno de España, 2022). The BNT162b2 messenger ribonucleic acid (mRNA) COVID-19 vaccine has shown optimal protection in the general population (Polack et al., 2020).Longitudinal dynamics of SARS-CoV-2 anti–receptor binding domain IgG antibodies in a wide population of health care workers after BNT162b2 vaccination
Two years after the initial spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and 1 year from the start of the coronavirus disease 2019 (COVID-19) vaccination campaign, approximately 416 million people have been infected and a total of approximately 10 billion vaccine doses have been administered worldwide ( https://covid19.who.int , accessed on February 15, 2022). Despite a wide range of technologies having been used, including live attenuated, viral vectored, messenger RNA (mRNA)–based, protein-based, and inactivated vaccines (Ng et al., 2020), BNT162b2 was the first vaccine authorized for emergency use by the European Medicines Agency ( https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu , accessed on May 5, 2022) and, in Italy, it was used for the first phase of the immunization program, primarily focused on health care workers (HCWs) (https://www.sa¬lute.gov.it/por¬tale/nuovocorona¬virus/dettaglioContenutiNuovoCoronavirus.jsp?lingua=italiano&id=5452&area=nuovoCoronavirus&menu=vuoto, accessed on May 5, 2022).Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia
Vaccinating against the SARS-CoV-2 virus to achieve high population immunity is essential to realise health and socio-economic goals driving the global COVID-19 vaccination strategy (World Health Organization. Strategy to achieve global COVID-19 vaccination by mid-2022.). In Malaysia, the national vaccination programme for COVID-19 began in February 2021 using a diverse platform of vaccines (Suah et al., 2021). It was demonstrated that they offer considerable protection, particularly against severe outcomes (Suah et al., 2022, 2021).Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
To evaluate the cost-effectiveness of a booster strategy in the United States.Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
Objective: To determine whether severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibody levels after the first dose of vaccine can predict the final antibody response, and whether this is dependent on the vaccine type.Methods: Sixty-nine recipients of BNT162b2 (Pfizer/BioNTech) and 55 recipients of AZD1222 (AstraZeneca), without previous infection or immunosuppressive medication, were included in this study. Antibody levels were quantified 3 weeks after the first dose [directly before boostering in the case of AZD1222 (11 weeks after the first dose)] and 3 weeks after the second dose using the Roche Elecsys SARS-CoV-2 S total antibody assay.The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
A two-dose regimen of BNT162b2, the Pfizer-BioNTech COVID-19 mRNA vaccine, was shown to reduce the risk of SARS-CoV-2 by around 95% in a randomized clinical trial and in a mass national vaccination program (Dagan et al., 2021; Polack et al., 2020). On 23 December 2020, Qatar started a national BNT162b2 rollout programme, in addition to existing COVID-19 public health control measures. The rollout initially prioritised healthcare workers, individuals aged ≥50 years, and those with chronic or immunosuppressive medical conditions.Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a global pandemic in a short period of time, imposing challenges on medical services, researchers, epidemiologists and policy makers about the nature of the virus; and posing challenges for a successful vaccine outcome (Umakanthan et al., 2020). SARS-CoV-2 is transmitted via respiratory droplets from face-to-face contact or contaminated surfaces. Although the role of aerosol spread in humans remains unclear, this mode of transmission is still a major concern (Ganyani et al., 2020).
